| 2.69 -0.05 (-1.82%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.29 | 1-year : | 3.56 |
| Resists | First : | 2.81 | Second : | 3.04 |
| Pivot price | 2.63  |
|||
| Supports | First : | 2.44 | Second : | 2.03 |
| MAs | MA(5) : | 2.68 |
MA(20) : | 2.68 |
| MA(100) : | 3.28 |
MA(250) : | 3.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61.7 |
D(3) : | 56.4 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 5.46 | Low : | 2.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ANIX ] has closed below upper band by 30.8%. Bollinger Bands are 63% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.78 - 2.79 | 2.79 - 2.8 |
| Low: | 2.62 - 2.64 | 2.64 - 2.65 |
| Close: | 2.66 - 2.69 | 2.69 - 2.71 |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Thu, 09 Apr 2026
Anixa Biosciences Reports Positive Clinical Trial Results for Cancer Vaccines - Intellectia AI
Thu, 09 Apr 2026
At April 16 event, Anixa will spotlight 74% immune response data - Stock Titan
Wed, 08 Apr 2026
ANIX Stock: Consistent 'Buy' Rating and Price Target Maintained - GuruFocus
Tue, 07 Apr 2026
74% vaccine response, CAR-T survival data on Anixa's April 14 agenda - Stock Titan
Tue, 07 Apr 2026
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 - PR Newswire
Mon, 06 Apr 2026
Breast cancer vaccine hit Phase 1 goals; Anixa cites CAR-T survival data - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 17.1 (%) |
| Shares Short | 1,150 (K) |
| Shares Short P.Month | 1,280 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.4 % |
| Return on Equity (ttm) | -68.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -8.41 |
| PEG Ratio | 0 |
| Price to Book value | 5.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|